Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical’s subsidiary, Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to begin clinical trials for XH-S004 tablets, a class 1 chemical medicine aimed at treating chronic obstructive pulmonary disease. This development signifies Fosun Pharma’s continued commitment to advancing pharmaceutical research, with XH-S004 also being tested for other indications such as non-cystic fibrosis bronchiectasis, reflecting potential growth in its R&D investments.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a Chinese joint stock limited company engaged in the pharmaceutical industry. It focuses on the research, development, and manufacturing of pharmaceuticals, particularly in areas like chronic diseases treatment.
YTD Price Performance: -6.25%
Average Trading Volume: 1,270
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.93B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.